RE:RE:RE:Yes -- Dare we say --- From Alzforum
Re Acumen, whenever I read their stuff I'm struck by the lack of any mention of misfolding. Of course the same could be said for other PMN competitors but it's more striking with Acumen because their stage of development is so close to that of Promis.
So when I read their stuff I'm looking for the sort of careful wording that disinvites any discussion of why certain oligomers are effectively more toxic with age? Acumen's discussions lead one to believe it must be simply age related immune system deterioration, that the always toxic but relatively rare species are just not getting cleared fast enough, with no thought for their possible self propagation. Kind of strange given how self-propagation features so prominently in every bio-sci-fi flick I've ever watched.
Which brings me to my actual point, which is when are we shareholders going to see management finally do some differentiation based promotion? I picked this company over others in the field because it's a pure play and I could see the logic of the core hypothesis which remains cutting-edge. And this is why it is SO FRUSTRATING that the company continues to bumble along as if Gene and Elliot remained in charge of promotion, still trying to ride the coattails of Biogen et al, for whatever self-serving reasons. So glad they can still pick up shares now at this rock bottom price, merry christmas.